PAR •
Healthcare •
Biotechnology •
Quote as of 09/11/2026 17:35
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangePAR
Market Capitalization35.49 mln
Float85.07 mln
Earnings Date07/16/2025
Piotroski F-Score
5
/ 9
Neutral
Beneish M-Score
-4.83
Highly reliable
Relative Strength
6
/ 100
Severely lagging
Debt / Equity
0.07
Debt-free
Pre-Tax Margin
-14%
Loss-making
ROE
-156
Deeply negative
Business Description
Nicox S.A. is a French eye care company focused on protecting and improving patients' vision through the development of new treatments. Its most advanced pipeline candidate, NCX 470, is an eye drop designed to reduce pressure inside the eye and is currently in Phase 3 clinical trials for glaucoma and ocular hypertension, while two additional treatments targeting dry eye disease and other eye conditions are in earlier stages of development. The company also markets two approved products, VYZULTA and ZERVIATE, which treat glaucoma, ocular hypertension, and eye allergies respectively. Founded in 1996 and based in Biot, France, Nicox operates across both domestic and international markets.
